Ansa Biotechnologies is discovering more sustainable and accurate ways of synthesizing DNA. Currently, DNA is manufactured using a chemical method for various downstream applications from biological research, therapies, diagnostics to biomanufacturing. Ansa are changing this method by pioneering their enzyme-based approach that will be faster, cleaner and more accurate. Ansa’s enzymatic oligonucleotide synthesizer, published in Nature Biotechnology, involves template-independent polymerase-nucleotide conjugates. This approach could revolutionize the way DNA is made.

<p>Claim company profile to add description to this page.</p>


Ansa Biotechnologies

Director of Product Management

DNA Synthesis Associate

Ansa Biotechnologies ties up $68M for DNA synthesis ...

"Trimming the Fat or Losing the Muscle? August 2024’s Biotech Layoff Frenzy Signals Strategic 'Adjustments' in the Name of Efficiency" - BSA bureau


              Ansa Biotechnologies Sets New Standard in Long, Complex DNA
            

Ansa Biotechnologies Names Jason T. Gammack as CEO Amid Advances in DNA Synthesis Technology - SynBioBeta

It was great to attend and sponsor an event that celebrates and supports the next generation of synthetic biology innovators! We're looking forward to the next one! Thanks, J. Craig Venter Institute and Tae Seok Moon for making it happen!

#SynBYSS #synbio #syntheticbiology 

Ansa Biotechnologies Sets New Standard in Long, Complex DNA

Ansa Biotechnologies Sets New Standard in Long, Complex DNA - Business Wire

 Compositions for enzymatic polynucleotide synthesis and methods of use 

 Ansa Biotechnologies Raises $68 Million In Series A Funding 

 Experts Bring a Faster and More Accurate Synthetic DNA Manufacturing Process 

 Oligonucleotide Synthesis Market: Advancements in DNA and ... 

Ansa Biotechnologies ties up $68M for DNA synthesis platform - Fierce Biotech

 Ansa Biotechnologies Raises $9.2 Million in Combined Seed and Pre-Seed Financing 

 Ansa Biotechnologies Sets New Standard in Long, Complex DNA 

 Ansa Biotechnologies partners with TeselaGen Biotechnology to enable commercial production of DNA products 

Ansa Biotechnologies Raises $9.2 Million in Combined Seed and Pre-Seed Financing - Business Wire

 Enzymatic DNA Synthesis Market 2022: Explore Top Factors that Will Boost the Global Market by 2028 

Ansa Biotechnologies Announces Successful de novo Synthesis of World’s Longest Oligonucleotide at 1005 Bases - Business Wire

Rewriting Cellular Communication: Advances in Synthetic Biology through Enzymatic DNA Synthesis for Protein Regulation - Fierce Biotech

 Ansa Biotechnologies to Showcase Early Access Customer Success at Upcoming Global Synthetic Biology Conference 

Ansa Biotechnologies Announces First Shipments of Complex Clonal DNA Sequences to Customers in Its Early Access Program - Technology Networks

 Methods of polynucleotide synthesis 

 Ansa Biotechnologies Pushes Limits of Complex DNA Synthesis with Launch of New Commercial Products 

 Ansa Biotechnologies Closes Oversubscribed $68 Million Series A Financing to Power the Next Era of DNA-Enabled Industries 


              Untangling the Complexities of Gene Synthesis for Longer, More Reliable DNA
            

We’re excited to welcome Ansa Biotechnologies, Inc. as a Bronze Level Sponsor for the International SynBYSS Conference! Join us at University of Hawai’i at Manoa from December 9-12, 2024. Don’t miss your chance to be part of this transformative experience-register today!

https://lnkd.in/eiQbZMZU

Ansa Biotechnologies Expands Successful Early Access Program for Complex DNA Synthesis - Business Wire

 Ansa Biotechnologies, Inc. on LinkedIn: Early Access 

With tremendous gratitude, we acknowledge all of those individuals who have dedicated their lives in service to our country. Thank you to everyone who is serving or has served. 🇺🇸

This Company Is Using Enzymatic DNA Synthesis To Usher In The Next Generation Of Synthetic Biology Innovation - Forbes

 Oligonucleotide Synthesis Market to Exceed 9.9 billion by ... 

Startup Ansa Bio lands $68M to go long with enzymes approach to DNA synthesis - MedCity News

 Reversible terminators 

World’s Longest Oligo Produced Using de novo Synthesis - Genetic Engineering & Biotechnology News


              Hate Rejection? So Do We. Here’s Why Ansa Can Make the Complex DNA Other Vendors Can’t.
            

The Ansa Biotechnologies team is ready for the holidays! From all of us, we wish you a season full of warmth, joy, and groundbreaking discoveries. Cheers to 2025! 🥂

#DNAsynthesis #longDNA #Ansamers #biotech #synbio #SyntheticDNA #DNAInnovation #complexDNA  #customDNA #HappyHolidays


 Ansa Biotechnologies Names Jason T. Gammack as CEO Amid Advances in DNA Synthesis Technology 

 DNA Supplier Ansa Biotechnologies Snares $68 Million 

 Ansa Biotechnologies Appoints Jason T. Gammack as CEO and Prepares for Launch of Rapid Enzymatic Synthesis ... 

 Modified terminal deoxynucleotidyl transferase polymerases 

 Ansa Biotechnologies Expands Successful Early Access Program for Complex DNA Synthesis 

A platform that allows protein secretion systems to achieve the same tuning capabilities seen in gene circuits? The Gao Lab has created just the thing, and it's made possible with enzymatic DNA synthesis by Ansa.

Connor Clayton Call of the Gao Lab at Stanford University will join Ansa co-founder and CSO Daniel Lin-Arlow to discuss the innovative Retained Endoplasmic Cleavable Secretion (#RELEASE) platform and its potential applications in re-wiring and regulating intercellular communication, with implications for cancer biology, immunology, and neuroscience.

They will also talk about the ins and outs of complex cloning strategies and the complexities involved with minimal sequence designs and repetitive motifs, which can be difficult without the modern DNA synthesis techniques that Ansa offers. 

🗓️ Register for the free Dec 10 webinar to learn more: https://lnkd.in/egZEGwWH

#DNAsynthesis #longDNA #Ansamers #biotech #synbio #SyntheticDNA #DNAInnovation #complexDNA  #customDNA #AnsamerAnswers

Ansa Biotech Raises $68M to Launch Customizable DNA Synthesis Service - BioSpace

 Enzymatic DNA Synthesis Market Key Manufacturers ... 

Ansa Biotechnologies Pushes Limits of Complex DNA Synthesis with Launch of New Commercial Products - Business Wire

𝗧𝗢𝗗𝗔𝗬! Mammalian synthetic biology is tricky, often requiring complex cloning strategies that can be difficult without modern DNA synthesis techniques.

The Gao Lab at Stanford have had to overcome these challenges in the development of the innovative Retained Endoplasmic Cleavable Secretion (𝗥𝗘𝗟𝗘𝗔𝗦𝗘) platform, which allows protein secretion systems to achieve the same tuning capabilities seen in gene circuits but focused solely on proteins.

It’s a great example of what enzymatic DNA synthesis can enable researchers to do, and we’re excited to highlight it in our next webinar.

🗓️ Tuesday, Dec. 10, 12pm ET

🔗 Sign up to watch live, or to get the recording: https://lnkd.in/egZEGwWH

#DNAsynthesis #longDNA #Ansamers #biotech #synbio #SyntheticDNA #DNAInnovation #complexDNA #customDNA #AnsamerAnswers

Synthesizing the Rules: How DNA Got Its Groove Back - SynBioBeta

Ansa Bio Appoints Lorna Neilson, Ph.D. as Chief Business Officer - Business Wire

 Ansa Biotechnologies Expands Leadership Team with Appointment of Jeremiah Hanes, Ph.D. as Senior Vice President of R&D 

Ansa Biotechnologies selects new SVP of R&D - MM+M Online

 Jason T. Gammack on LinkedIn: I'm thrilled to be joining Ansa Biotechnologies, Inc. as CEO. Daniel… | 53 comments 

Ansa Bio Appoints Dr. Matthew McManus as Chair of the Board - Business Wire

 Ansa Biotechnologies wants to usher in a new era of DNA manufacturing 

Ansa Biotechnologies sets new standard in long complex DNA - SelectScience

Enzymatic DNA Synthesis: Going to Great Lengths - The Scientist

Ansa Biotechnologies Closes Oversubscribed $68 Million Series A Financing to Power the Next Era of DNA-Enabled Industries - Business Wire


              At Ansa, We're Enabling New Possibilities in Biological Engineering
            

Ansa Biotechnologies

Business:

About: